Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete | ||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Unituxin | dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | ||
Vabysmo | faricimab | Diabetic Macular Edema | Reimburse with clinical criteria and/or conditions | Complete | ||
Vantas | Histrelin acetate | Cancer, prostate | Do not list | Complete |